Nathan Foster

Dr. Nathan Foster


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in Cancer Biology & Therapy
Verified
Journal Article
Open access
PDF file
JPJae Myung Park
Jae Myung Park
SHShengbing Huang
Shengbing Huang
TWTsung-Teh Wu
Tsung-Teh Wu
NFNathan Foster
Nathan Foster
FSFrank Sinicrope
Frank Sinicrope
Autophagy is a cellular degradation process that can be activated in tumor cells to confer stress tolerance. During autophagy initiation and autophagosome formation, Beclin 1 binds microtubule-associated protein-1 light chain 3 (LC3I) that is converted to its membrane-bound form (LC3II) and interacts with the ubiquitin-binding protein p62/sequestosome 1 (SQSTM1). We determined the association of Beclin 1, LC3 and p62 protein expression with clinical outcome in resected stage II and III colon carcinomas (n = 178) from participants in 5-fluororuacil (5-FU)-based adjuvant therapy trials. The immunopercentage for each marker was determined and dichotomized for analysis with overall survival (OS) using Cox models. We found that autophagy markers localized to the tumor cell cytoplasm and showed increased expression relative to normal epithelial cells. Overexpression of Beclin 1, LC3 and p62 proteins were detected in 69%, 79% and 85% of tumors, respectively. Expression levels were not significantly associated with clinicopathological variables. In a multivariable analysis adjusting for tumor grade, stage and patient age, Beclin 1 overexpression was independently associated with worse OS [hazard ratio (HR), 1.82; 95% confidence interval (CI), 1.0–3.3; p = 0.042] in patients who received 5-FU-based adjuvant therapy. Neither LC3 nor p62 overexpression was prognostic. In conclusion, Beclin 1 overexpression was associated with reduced survival in colon cancer patients treated with adjuvant 5-FU. These data are consistent with preclinical evidence indicating that autophagy can protect colon cancer cells from 5-FU and support the targeting of autophagy for therapeutic advantage in this malignancy.

4 June 2009 in Cancer
Verified
Journal Article
Open access
PDF file
NFNathan Foster
Nathan Foster
SMSumithra J. Mandrekar
Sumithra J. Mandrekar
SSSteven E. Schild
Steven E. Schild
GNGarth D. Nelson
Garth D. Nelson
KRKendrith M. Rowland
Kendrith M. Rowland
AAAlex A. Adjei
Alex A. Adjei
BACKGROUND: An analysis of 14 small cell lung cancer (SCLC) trials was performed to improve the current understanding of potential prognostic factors for overall survival (OS) and progression‐free survival (PFS) in groups of patients with limited‐stage disease SCLC (LD‐SCLC) and extensive‐stage disease SCLC (ED‐SCLC) separately.METHODS: Data on 688 patients with LD‐SCLC and 910 patients with ED‐SCLC were included. Clinical and laboratory factors were tested for their prognostic significance using Cox regression models that were stratified by protocol. Recursive partitioning and amalgamation (RPA) analyses were used to identify prognostic subgroups.RESULTS: Poorer performance status (PS) led to worse OS and PFS in the ED‐SCLC group but not in the LD‐SCLC group. The prognostic impact of PS was strong for men but weak for women in the ED‐SCLC group (interaction P value <.012 for OS and PFS). Other negative prognostic factors included increased age and men for the LD‐SCLC group and increased age, men, increased number of metastatic sites at baseline, and increased creatinine levels for the ED‐SCLC group. In patients with the ED‐SCLC, RPA analyses identified 5 subgroups with different prognosis based on baseline PS, creatinine levels, sex, and the number of metastatic sites.CONCLUSIONS: The current pooled analysis identified baseline creatinine levels and the number of metastatic sites as important prognostic factors in patients with ED‐SCLC in addition to the well established factors of sex, age, and PS. There was a significant interaction between sex and PS within the ED‐SCLC group, suggesting that PS is highly prognostic in men but has no significant impact in women. Within the LD‐SCLC group, only age and sex were identified as important prognostic factors. RPA analyses confirmed many of these findings. Cancer 2009. © 2009 American Cancer Society.

19 October 2010 in Cancer
Verified
Journal Article
Open access
PDF file
NFNathan Foster
Nathan Foster
YQYingwei Qi
Yingwei Qi
QSQian Shi
Qian Shi
JKJames E. Krook
James E. Krook
JKJohn W. Kugler
John W. Kugler
SMSumithra J. Mandrekar
Sumithra J. Mandrekar
BACKGROUND: The authors investigated the putative surrogate endpoints of best response, complete response (CR), confirmed response, and progression‐free survival (PFS) for associations with overall survival (OS), and as possible surrogate endpoints for OS.METHODS: Individual patient data from 870 untreated extensive stage small‐cell lung cancer patients participating in 6 single‐arm (274 patients) and 3 randomized trials (596 patients) were pooled. Patient‐level associations between putative surrogate endpoints and OS were assessed by Cox models using landmark analyses. Trial‐level surrogacy of putative surrogate endpoints were assessed by the association of treatment effects on OS and individual putative surrogate endpoints. Trial‐level surrogacy measures included:R2from weighted least squares regression model, Spearman correlation coefficient, andR2from bivariate survival model (CopulaR2).RESULTS: Median OS and PFS were 9.6 (95% confidence interval [CI], 9.1‐10.0) and 5.5 (95% CI, 5.2‐5.9) months, respectively; best response, CR, and confirmed response rates were 44%, 22%, and 34%, respectively. Patient‐level associations showed that PFS status at 4 months was a strong predictor of subsequent survival (hazard ratio [HR], 0.42; 95% CI, 0.35‐0.51; concordance index 0.63;P< .01), with 6‐month PFS being the strongest (HR, 0.41; 95% CI, 0.35‐0.49; concordance index, 0.66,P< .01). At the trial level, PFS showed the highest level of surrogacy for OS (weighted least squaresR2= 0.79; CopulaR2= 0.80), explaining 79% of the variance in OS. Tumor response endpoints showed lower surrogacy levels (weighted least squaresR2≤0.48).CONCLUSIONS: PFS was strongly associated with OS at both the patient and trial levels. PFS also shows promise as a potential surrogate for OS, but further validation is needed using data from a larger number of randomized phase 3 trials. Cancer 2011. © 2010 American Cancer Society.

1 July 2015 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
PDF file
NFNathan Foster
Nathan Foster
LRLindsay A. Renfro
Lindsay A. Renfro
SSSteven E. Schild
Steven E. Schild
MRMary W. Redman
Mary W. Redman
XWXiaofei F. Wang
Xiaofei F. Wang
SMSumithra J. Mandrekar
Sumithra J. Mandrekar

20 May 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
FSFrank Sinicrope
Frank Sinicrope
TSThomas C. Smyrk
Thomas C. Smyrk
NFNathan Foster
Nathan Foster
JMJeffrey P. Meyers
Jeffrey P. Meyers
STStephen N. Thibodeau
Stephen N. Thibodeau
SASteven Alberts
Steven Alberts
3518 Background: High levels of TILs are associated with favorable prognosis in some solid tumors. We examined TIL levels in CC subtyped using mutations in KRAS or BRAF oncogenes as well as DNA mismatch repair (MMR) status, and examined association with patient (pt) prognosis. Methods: Stage III CC (N=2293) from a randomized trial of adjuvant FOLFOX + cetuximab (NCCTG N0147) were analyzed for TILs; dichotomized as high (> 4 TILs per HPF) vs low at light microscopy. We determined the association of TILs with clinicopathological features, mutations in KRAS exon 2 or BRAF(V600E), MMR status, and DFS by multivariate Cox regression analyses. Results: Higher TIL densities were found in tumors with wild-type (wt) vs mutated (mut) KRAS (p=.038) or BRAF (p<.0001). Among tumors with mut BRAFV600E or mut KRAS, high vs low TILs were found in 19.2% and 9.5%, respectively. In tumors with mut BRAF, high TILs were detected in 31.2% of dMMR vs 9.5% of pMMR cancers (p<.0001). TILs were increased 3.6-fold in dMMR vs proficient (p) MMR tumors (p<.0001). Also associated with high vs low TILs were female vs male (p=.011), white vs non-white (p=.008), proximal vs distal (p<.0001), lower T stage (p=.004), fewer positive/examined nodes (p=.015), and high vs low grade (p=.0001). High vs low TILs were associated with better DFS overall [HR=0.76 (0.57-1.01), p=0.047], and among tumors with wt KRAS [HR= 0.61 (0.41-.89), p=.006] or wt KRAS and BRAF [HR= 0.56 (0.34-.92), p=.013]. TILs were not prognostic in tumors with mut KRAS (p=.71; TIL*KRAS interaction p= 0.097) or mut BRAF (p=.18). High vs low TILs were associated with favorable DFS in pt tumors with dMMR [HR= 0.55 (.30-1.01), p=.045], but not pMMR (p=.301; interaction p=0.17]. No significant differences were found by treatment arm. Conclusions: Significantly lower TILs are found in tumors with mut vs wt KRAS or BRAF suggesting reduced immunogenicity. Among tumors with wt, but not mut, KRAS and BRAF, high vs low TILs were associated with better survival. TILs were increased 3.6-fold in dMMR vs pMMR, and favorably prognostic within dMMR pts. These results for wt tumors and those with dMMR suggest that immune activation improves survival outcomes.

1 July 2006
Verified
Journal Article
Closed access
SMSumithra J Mandrekar
Sumithra J Mandrekar
DNDonald W Northfelt
Donald W Northfelt
SSSteven E. Schild
Steven E. Schild
NFNathan Foster
Nathan Foster
BBBrian Bot
Brian Bot
JJJames R Jett
James R Jett